Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Regorafenib in patients with unresectable hepatocellular carcinoma (uHCC) in routine clinical practice: Exploratory analysis of overall survival (OS) in the prospective, observational REFINE study.
Presenter
Richard S. Finn, MD
David Geffen School of Medicine at UCLA
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03289273
DOI
10.1200/JCO.2022.40.4_suppl.433
Abstract #
433
Poster Bd #
C1
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2021 ASCO Annual Meeting
IMbrave150: Exploratory analysis to examine the association between treatment response and overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor).
Speaker: Michel Ducreux, MD, PhD
Videos & Slides
2023 ASCO Gastrointestinal Cancers Symposium
IMbrave150: Exploratory analysis to examine the association between bevacizumab (bev) ever being skipped and bev never being skipped in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo) + bev in a global phase 3 study.
Speaker: Masatoshi Kudo, MD, PhD
Videos & Slides
2022 ASCO Gastrointestinal Cancers Symposium
Regorafenib plus nivolumab as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Multicenter phase 2 trial (RENOBATE).
Speaker: Changhoon Yoo, MD, PhD
Speaker: Albert C. Lockhart, MD